These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10408846)

  • 1. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
    Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
    Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma].
    Viganò MG; Lissoni P; Barni S; Tancini G; Scardino E; Favini P; Baccalini A; Verweij F; Strada G; Rocco F
    Arch Ital Urol Androl; 1995 Apr; 67(2):143-7. PubMed ID: 7787856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy.
    Fumagalli LA; Vinke J; Hoff W; Ypma E; Brivio F; Nespoli A
    J Immunother; 2003; 26(5):394-402. PubMed ID: 12973028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
    Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
    Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2.
    Lissoni P; Barni S; Andres M; Scardino E; Vigoré L; Vezzo R; Rescaldani R; Tancini G
    Tumori; 1994 Aug; 80(4):283-5. PubMed ID: 7974799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
    Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
    Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
    Ahmed FY; Leonard GA; A'Hern R; Taylor AE; Lorentzos A; Atkinson H; Moore J; Nicolson MC; Riches PG; Gore ME
    Br J Cancer; 1996 Oct; 74(7):1109-13. PubMed ID: 8855983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
    Bonfanti A; Lissoni P; Bucovec R; Rovelli F; Brivio F; Fumagalli L
    Int J Biol Markers; 2000; 15(2):161-4. PubMed ID: 10883890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.
    Böhm M; Ittenson A; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
    Eur Urol; 2002 Apr; 41(4):458-67; discussion 467-8. PubMed ID: 12074819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
    Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
    Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
    J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
    J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
    Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
    Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 is a survival prognostic factor in renal cell carcinoma.
    Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
    Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
    J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous interleukin-2 in combination with vinblastine for metastatic renal cancer: cytolytic activity of peripheral blood lymphocytes.
    Indrová M; Bubeník J; Jakoubková J; Símová J; Jandlová T; Helmichová E; Benesová K; Hesová M; Stáhalová V
    Neoplasma; 1994; 41(4):197-200. PubMed ID: 7935991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.